Other News To Note
Monday, August 8, 2011
MolMed SpA, of Milan, Italy, signed an agreement with GlaxoSmithKline plc, of London, and will develop a production process for an investigational gene therapy for adenosine deaminase deficiency-severe combined immune deficiency, a rare, life-threatening disease that affects approximately 350 children worldwide. MolMed said it will receive as much as $7.78 million in revenue over a two-year period.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.